Jennifer Doudna Headshot
Report a problem with this profile
[email protected]

Jennifer Doudna    

Technology Co-Inventor, CRISPR- Cas9

Dr. Jennifer Doudna is redefining what’s possible with genetic engineering. As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Doudna and her colleagues rocked the research world in 2012 by uncovering a simple way of editing the DNA of any organism using a common protein found in bacteria. Doudna’s novel approach of having proteins proactively ‘snip’ DNA into new sequences has opened the floodgates of possibility for non-human and human applications including assisting researchers in the fight against HIV, sickle cell anemia and cystic fibrosis. Today Doudna is widely recognized as a leading expert on RNA-protein biochemistry, CRISPR biology, and genome engineering, and currently holds memberships with the Howard Hughes Medical Institute, and Lawrence Berkeley National Laboratory, along with the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences.

Jennifer Doudna, Ph.D is a professor of molecular and cell biology and chemistry at the University of California, Berkeley, where she holds the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences, and is a Howard Hughes Medical Institute investigator. As a co-inventor of CRISPR-Cas9, a process that revolutionized gene editing, she has received numerous honors including the NSF Waterman Award, the FNIH Lurie Prize, the Paul Janssen Award for Biomedical Research, the Breakthrough Prize in Life Sciences, the Gruber Prize in Genetics, the Massry Prize, the Heineken Award, the Gairdner Award, the Nakasone Award, and the L’Oreal-UNESCO International Prize for Women in Science. She is an elected member of the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Inventors, and a Foreign Member of the Royal Society, and she was named one of Time Magazine’s 100 most influential people in the world in 2015.


DNA-Editing Company Goes Public While Nasty Patent Fight Roars On

The Boston biotech Editas Medicine went public on Wednesday armed with unusually big ambitions and resources: It aims to cure genetic diseases with a hot and controversial technology, called CRISPR, which allows scientists to precisely “edit” DNA. Before going public, the company was backed by more than $160 million in private money from Bill Gates, Google Ventures, and more than a dozen other investors. But all of that now rests on a heated intellectual property feud between two renowned scientists, each of whom claim to have invented CRISPR. One is Jennifer Doudna at the University of California at Berkeley, the other Feng Zhang of the Broad Institute and the Massachusetts Institute of Technology. But they weren’t always rivals: They co-founded Editas in fall 2013.

Jennifer Doudna Has Won A CRISPR Gene-Editing Patent

A biotech startup has been issued a patent that involves CRISPR, the breakthrough gene-editing method that has sparked a nearly unprecedented intellectual property feud between some of the country’s biggest institutions. But it’s unclear what effect, if any, the patent will have on that fight.

Related Speakers View all

More like Jennifer